COMMUNIQUÉS West-GlobeNewswire

Longeveron to Present at Biotech Showcase 2025

18/12/2024 - 15:10

MIAMI, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related [...]

Braille Institute Library to Host Livestream Event with Pulitzer Prize Finalist Andrew Leland on January 16, 2025

18/12/2024 - 15:00

Leland to discuss his best-selling book, “The Country of the Blind: A Memoir at the End of Sight” LOS ANGELES, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The Braille Institute Library is excited to announce a special event [...]

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

18/12/2024 - 15:00

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging Novartis to [...]

Rafarma pharmaceutical updates

18/12/2024 - 15:00

Sheridan, Wyoming, USA, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) Dear Rafarma shareholders, We apologize for the delay in providing information about the company's activities in recent [...]

T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

18/12/2024 - 15:00

Multiple instrument sale demonstrates growing market penetration of T2 Biosystems’ sepsis tests LEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of [...]

The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed

18/12/2024 - 14:59

Bagsværd, Denmark, 18 December 2024 — Today, Novo Nordisk completed its acquisition of three manufacturing sites from Novo Holdings A/S. The completion follows the finalisation of Novo Holdings’ acquisition of Catalent [...]

Akari Therapeutics Announces Key Leadership Appointments

18/12/2024 - 14:51

Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) today announced [...]

Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology

18/12/2024 - 14:30

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

18/12/2024 - 14:30

JERUSALEM, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , announced today [...]

Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model

18/12/2024 - 14:30

FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today [...]

Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor

18/12/2024 - 14:30

Trial will evaluate the safety, pharmacokinetics and pharmacodynamics of RPT1G in adult healthy volunteers in anticipation of their upcoming oncology trial to treat patients with acute myeloid leukemia (AML) and high- [...]

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

18/12/2024 - 14:30

- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, [...]

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

18/12/2024 - 14:18

Clinical Data from First Subject Dosed Twice Daily with QRX003 in Open Label Study Is Positive at Mid-point of Testing Significant Improvement in Skin Appearance Observed in Pediatric Study after Only 12 Days of Dosing [...]

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

18/12/2024 - 14:00

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the [...]

Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

18/12/2024 - 14:00

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna , a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., [...]

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

18/12/2024 - 14:00

Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those granted for SCN2A [...]

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

18/12/2024 - 14:00

Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful repeat administration of [...]

Streamline Health® Reports Fiscal Third Quarter 2024 Financial Results, Accelerates Anticipated Adjusted EBITDA Breakeven Timeline

16/12/2024 - 22:33

Net loss of ($2.5 million) during the third quarter of fiscal 2024 compared to a net loss of ($11.9 million) during the third quarter of fiscal 2023 Company reiterated $15.5 million implemented SaaS ARR adjusted EBITDA [...]

Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year

16/12/2024 - 22:30

TARRYTOWN, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its sixth consecutive inclusion in the Dow Jones Sustainability World Index (DJSI World) and fifth [...]